Paper Details

  1. Home
  2. Paper Details

Dosimetry in myeloablative (90)Y-labeled ibritumomab tiuxetan therapy: possibility of increasing administered activity on the base of biological effective dose evaluation. Preliminary results.

Author: AlibertiGianluca, BavusiSergio, BombardieriEmilio, BottaFrancesca, ChiesaCarlo, ColivaAngela, DevizziLiliana, Di BettaErika, GianniAlessandro Massimo, GuidettiAnna, MaccauroMarco, SeregniEttore

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

(90)Y-labeled ibritumomab tiuxetan was administered in activity per kilo twice- and three times the maximum tolerable dose suggested for nonmyeloablative treatments. The dosimetric aim was to correlate possible extramedullary toxicities to the organ-absorbed doses or to the biologic effective dose (BED).
Paper Details　
Original Abstract of the Article :
In our multicentric ongoing phase I activity escalation study, (90)Y-labeled ibritumomab tiuxetan (Ze-valin was administered in activity per kilo twice- and three times the maximum tolerable dose of 15 MBq/kg suggested for nonmyeloablative treatments by the U.S. registration study. The radioinduced ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1089/cbr.2007.302

データ提供：米国国立医学図書館（NLM）

Myeloablative Therapy with (90)Y-labeled Ibritumomab Tiuxetan: A New Approach to Dosing

This research explores the potential for increasing the administered activity of (90)Y-labeled ibritumomab tiuxetan (Ze-valin), a radioimmunotherapy used for treating certain types of cancer. The study focuses on the use of myeloablative doses, high doses that can cause significant bone marrow suppression. The authors investigate the feasibility of increasing the administered activity based on the biological effective dose (BED), a metric that accounts for dose rate and tissue repair mechanisms. The study's preliminary results suggest that increasing the administered activity may be possible while managing the associated risks through stem cell autografting.

Navigating the Sands of Dosing Optimization

The study's findings suggest a new approach to dosing (90)Y-labeled ibritumomab tiuxetan, potentially leading to more effective treatment outcomes while managing the risks associated with high-dose therapy. The authors' focus on the biological effective dose (BED) provides a valuable framework for optimizing dosing strategies and maximizing the therapeutic benefits of this radioimmunotherapy.

The Desert of Cancer Treatment: Optimizing Dosing Strategies

Navigating the desert of cancer treatment often involves balancing the benefits and risks of various therapies. This research explores the potential for optimizing dosing strategies for (90)Y-labeled ibritumomab tiuxetan, aiming to maximize treatment effectiveness while minimizing side effects. Remember, the desert of cancer treatment can be navigated with a watchful eye, open communication with your healthcare provider, and a commitment to receiving the best possible care.

Dr.Camel's Conclusion

This research delves into the potential for optimizing dosing strategies for (90)Y-labeled ibritumomab tiuxetan, a radioimmunotherapy used for treating certain types of cancer. The study's focus on the biological effective dose (BED) provides a valuable framework for optimizing dosing strategies and maximizing the therapeutic benefits of this treatment.

Date :
  1. Date Completed 2007-08-20
  2. Date Revised 2016-11-24
Further Info :

Pubmed ID

17627419

DOI: Digital Object Identifier

10.1089/cbr.2007.302

Related Literature

Article Analysis
・Effects of ibritumomab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.